The North America sepsis diagnostics market is expected to grow from US$ 279.06 million in 2021 to US$ 513.33 million by 2028. It is estimated to record a CAGR of 9.1% from 2021 to 2028.
High Incidence of Sepsis due to Increasing Nosocomial Infections Drives North America Sepsis Diagnostics Market
Sepsis, fundamentally caused by infection, predominantly affects immunocompromised people, including those taking chemotherapy, having a splenectomy, and suffering from AIDS, diabetes, and other chronic illnesses. Notably, nosocomial infections are the primary cause of morbidity and mortality among hospitalized patients. According to the "2020 National and State Healthcare-Associated Infections Progress Report" published by the Centers for Disease Control and Prevention (CDC) in 2021, the US recorded about 24%, 35%, and 15% increases in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, respectively, between 2019 and 2020.
As per a report published by the Global Sepsis Alliance (GSA), nearly 26 million people develop sepsis every year, and approximately 8 million deaths are reported due to sepsis across the world. The rising bloodstream infections will therefore increase the adoption of sepsis diagnostic products. Moreover, deaths often stem from diarrheal diseases or lower respiratory infections. Most deaths can be prevented through early diagnosis and appropriate clinical management. Thus, the high incidence rate of sepsis is expected to boost the demand for sepsis diagnostic products, which would support the North America sepsis diagnostics market growth during the forecast period.
Download our Sample PDF Report
@ https://www.businessmarketinsights.com/sample/BMIRE00025664
North America Sepsis Diagnostics Strategic Insights
Strategic insights for the North America Sepsis Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
North America Sepsis Diagnostics Market Segmentation
North America Sepsis Diagnostics Market By Product
Instruments
Reagents and Assays
Blood Culture Media
Software
North America Sepsis Diagnostics Market By Technology
Molecular Diagnostics
By Flow Cytometry, Microfluidics, Immunoassay, Biomarkers, Microbiology)
North America Sepsis Diagnostics Market By Method
Automated Diagnostics and Conventional Diagnostics
North America Sepsis Diagnostics Market By Test Type
Point-of-Care Tests and Laboratory Tests
North America Sepsis Diagnostics Market Regions and Countries Covered
North America
US
Canada
Mexico
North America Sepsis Diagnostics Market leaders and key company profiles
Abbott
BD
bioMerieux SA
Danaher (Beckman Coulter)
- HOFFMANN-LA ROCHE LTD.
Immunexpress Inc.
Luminex Corporation
T2 Biosystems, Inc.
THERMO FISHER SCIENTIFIC INC.
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
